The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISAL 2023 | Addressing leukemic transformation in MDS: ongoing challenges and future outlooks
David Sallman, MD, Moffitt Cancer Center, Tampa, FL, discusses the importance of addressing leukemic transformation (LT) in myelodysplastic syndromes (MDS), emphasizing the poor outcomes observed in these patients. Dr Sallman then highlights the promise of novel combination approaches being explored in MDS and how these may be a valuable strategy to prevent transformation to acute myeloid leukemia (AML). This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
